http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2011005974-A3

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1e96496a9949403e2af2ca913e65bfec
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0b4fb1bf10f9a83c8574c5556b9a422c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_64faaf83cf81183b6d9e8716f2bcd9fa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c683e82947e6ff71ef3717e3cee373a4
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2502-243
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2533-74
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2533-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2517-10
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N11-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0682
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0012
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0609
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-071
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N11-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12M3-00
filingDate 2010-07-08-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_daf0d16659d3810a6e59abee103bbe82
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f83a1762472416b3f7452a80511e98ae
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_882d054c7044eb234009efda9aa22b52
publicationDate 2011-05-12-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2011005974-A3
titleOfInvention Interpenetrating biomaterial matrices and uses thereof
abstract The present invention relates to matrices (e.g., fibrin-alginate matrices; fibrin-alginate-matrigel matrices) for culture of cells, organs (e.g., ovary or fragment thereof), cells and cell aggregates (e.g., ovarian follicles, embryoid bodies), and tissues. In some embodiments, protease inhibitors e.g., aprotinin) are used to prevent the degradation of fibrin.
priorityDate 2009-07-08-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2004014969-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2007028258-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005041942-A2
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID439199
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP00974
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID16130295
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID415966231
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID422600743

Total number of triples: 35.